The resale registration creates massive near-term overhang — the registered shares equal ~99% of current float, and the $3.25 warrant exercise price is more than double the current $1.55 stock price, making cash exercise unlikely. Monitor for any Armistice sales under the registration, which would further pressure the stock. The company's cash runway into early 2027 and going concern status suggest additional dilutive financing is likely before year-end 2026.
Executive Summary
Decoy Therapeutics filed an S-1 registration statement to register up to 2,368,868 shares of common stock for resale by Armistice Capital Master Fund Ltd., the sole selling stockholder. These shares are issuable upon exercise of New Warrants issued as inducement for the immediate cash exercise of existing Series B warrants, which generated $3.85 million in gross proceeds. The company is a pre-clinical stage biotech with a going concern warning, only ~$8.0 million in cash (of which $2.5 million is restricted), and faces massive potential dilution as the registered shares alone nearly equal the current outstanding float.
Key Facts
- S-1 registers up to 2,368,868 shares for resale by Armistice Capital Master Fund Ltd., representing ~99% of the current 2,385,282 shares outstanding.
- New Warrants have an exercise price of $3.25 per share, expire in 5 years, and are subject to a 4.99% beneficial ownership limitation.
- The company received $3.85 million in gross proceeds from the exercise of Existing Series B Warrants at a reduced price of $3.25/share.
- Cash, cash equivalents and restricted cash as of September 30, 2026 was approximately $8.0 million, with $2.5 million restricted for Gates Foundation use.
- Auditor Ernst & Young LLP included a going concern explanatory paragraph in the FY2025 audit report.
- Company expects existing cash to fund operations only into early 2027.
- Stock closed at $1.55 on October 6, 2026, well below the $3.25 warrant exercise price.
- Armistice Capital Master Fund Ltd. beneficially owns 64.68% of shares prior to the offering (assuming full warrant exercise).
- Company is under a Nasdaq mandatory panel monitor through March 31, 2027 due to prior non-compliance with listing requirements.
- No revenue from product sales; pre-clinical stage biotech with IMP3ACT platform and legacy small molecule candidates SP-3164 and seclidemstat.
Financial Impact
Potential dilution of ~99% of current outstanding shares from the resale registration alone, plus additional overhang from 2,922,730 other warrants at a weighted-average exercise price of $10.59 and 390,604 preferred shares convertible pending stockholder approval. Cash runway only into early 2027 with $8.0 million total cash.
Risk Factors
- Massive dilution risk: registered shares nearly equal current outstanding float, and total potential dilution from all warrants and preferred stock conversion could exceed 200% of current shares.
- Going concern risk: cash only sufficient into early 2027; no product revenue; may need additional dilutive financing.
- Nasdaq delisting risk: company under mandatory panel monitor through March 2027; stock at $1.55 faces bid price compliance risk.
- Warrant exercise unlikely at current price: $3.25 exercise price vs $1.55 stock price means cash exercise is deeply out-of-the-money.
- Pre-clinical stage: no approved products, no revenue, pipeline risk with IMP3ACT platform and legacy candidates.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001193125-26-417053 |
| Document: dcoy-ex5_1.htm | 0001193125-26-417053 |
| Document: dcoy-exfiling_fees.htm | 0001193125-26-417053 |
| Document: dcoy-ex23_1.htm | 0001193125-26-417053 |
| Document: 0001193125-26-417053-index-headers.html | 0001193125-26-417053 |
| Document: 0001193125-26-417053-index.html | 0001193125-26-417053 |
| Document: 0001193125-26-417053.txt | 0001193125-26-417053 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | EFFECT | $1.17 $0.9100 | ▼ −22.22% | ▼ −22.08% | $0.9200 (−21.37%) |
Oct 7, 2026 19d ago | S-1 | $1.52 $1.23 | ▲ +19.08% | ▲ +18.80% | $0.9200 (+39.47%) |
Sep 23, 2026 4w ago | 8-K | $3.11 $1.86 | ▲ +40.35% | ▲ +39.94% | $0.9200 (+70.42%) |
Aug 4, 2026 11w ago | DEFA14A | $4.19 $3.60 | ▼ −14.08% | ▼ −14.43% | $0.9200 (−78.04%) |
Jul 20, 2026 14w ago | EFFECT | $5.31 $3.74 | ▼ −29.50% | ▼ −29.10% | $0.9200 (−82.66%) |
Jun 29, 2026 17w ago | 8-K | $9.59 $7.25 | ▲ +24.40% | ▲ +25.79% | $0.9200 (+90.41%) |
Jun 25, 2026 17w ago | EFFECT | $5.92 $7.62 | ▲ +28.76% | ▲ +27.20% | $0.9200 (−84.45%) |
Jun 4, 2026 20w ago | DEFA14A | $6.71 $5.90 | ▼ −12.07% | ▼ −9.52% | $0.9200 (−86.29%) |
Apr 30, 2026 25w ago | 10-K/A | $6.05 $6.01 | ▼ −0.66% | ▼ −2.39% | $0.9200 (−84.79%) |
Apr 2, 2026 29w ago | 8-K | $5.80 $5.84 | ▲ +0.69% | ▼ −2.93% | $0.9200 (−84.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers